China NMPA Drug Inspection - Guizhou Baili Pharmaceutical Group Co., Ltd. - Mu Xiang Shun Qi Wan

China NMPA drug inspection for Guizhou Baili Pharmaceutical Group Co., Ltd. published January 22, 2020. Drug: Mu Xiang Shun Qi Wan. The Ningxia Hui Autonomous Region Drug Administration announced the results of its regional drug sampling inspections co

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Guizhou Baili Pharmaceutical Group Co., Ltd.

Inspection Date

Unknown Date

Product Type

ID: af6a8899-1757-44fc-a29b-a828284de704

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox